Kiesslich, Tobias <br/><br/>
HDAC inhibitors in liver cancer: which route to take?  [electronic resource] 

 -  Expert review of gastroenterology & hepatology  Jun 2019 
 - 515-517 p.  digital 
<br/><br/> Publication Type: Editorial 
<br/><br/><label>ISSN: </label>1747-4132 
<br/><br/><label>Standard No.: </label>10.1080/17474124.2019.1605289  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antineoplastic Combined Chemotherapy Protocols--adverse effects<br/>Carcinoma, Hepatocellular--drug therapy<br/>Clinical Decision-Making<br/>Disease Progression<br/>Epigenesis, Genetic--drug effects<br/>Histone Deacetylase Inhibitors--adverse effects<br/>Humans<br/>Liver Neoplasms--drug therapy<br/>Patient Selection<br/>Treatment Outcome